King's College London

Research portal

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

Research output: Contribution to journalArticle

Standard

Doxorubicin in advanced breast cancer : influence of schedule on response, survival and quality of life. / Richards, M A; Hopwood, P; Ramirez, A J; Twelves, C J; Ferguson, J; Gregory, W M; Swindell, R; Scrivener, W; Miller, J; Howell, A; Rubens, R.D.

In: European Journal of Cancer, Vol. 28A, No. 6-7, 1992, p. 1023-8.

Research output: Contribution to journalArticle

Harvard

Richards, MA, Hopwood, P, Ramirez, AJ, Twelves, CJ, Ferguson, J, Gregory, WM, Swindell, R, Scrivener, W, Miller, J, Howell, A & Rubens, RD 1992, 'Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life', European Journal of Cancer, vol. 28A, no. 6-7, pp. 1023-8. https://doi.org/10.1016/0959-8049(92)90447-A

APA

Richards, M. A., Hopwood, P., Ramirez, A. J., Twelves, C. J., Ferguson, J., Gregory, W. M., ... Rubens, R. D. (1992). Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. European Journal of Cancer, 28A(6-7), 1023-8. https://doi.org/10.1016/0959-8049(92)90447-A

Vancouver

Richards MA, Hopwood P, Ramirez AJ, Twelves CJ, Ferguson J, Gregory WM et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. European Journal of Cancer. 1992;28A(6-7):1023-8. https://doi.org/10.1016/0959-8049(92)90447-A

Author

Richards, M A ; Hopwood, P ; Ramirez, A J ; Twelves, C J ; Ferguson, J ; Gregory, W M ; Swindell, R ; Scrivener, W ; Miller, J ; Howell, A ; Rubens, R.D. / Doxorubicin in advanced breast cancer : influence of schedule on response, survival and quality of life. In: European Journal of Cancer. 1992 ; Vol. 28A, No. 6-7. pp. 1023-8.

Bibtex Download

@article{c67dcf74f2a24872b4856aabcd5b00ea,
title = "Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life",
abstract = "The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.",
author = "Richards, {M A} and P Hopwood and Ramirez, {A J} and Twelves, {C J} and J Ferguson and Gregory, {W M} and R Swindell and W Scrivener and J Miller and A Howell and R.D. Rubens",
year = "1992",
doi = "10.1016/0959-8049(92)90447-A",
language = "English",
volume = "28A",
pages = "1023--8",
journal = "European Journal of Cancer",
issn = "1879-0852",
publisher = "Elsevier Limited",
number = "6-7",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Doxorubicin in advanced breast cancer

T2 - influence of schedule on response, survival and quality of life

AU - Richards, M A

AU - Hopwood, P

AU - Ramirez, A J

AU - Twelves, C J

AU - Ferguson, J

AU - Gregory, W M

AU - Swindell, R

AU - Scrivener, W

AU - Miller, J

AU - Howell, A

AU - Rubens, R.D.

PY - 1992

Y1 - 1992

N2 - The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.

AB - The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.

U2 - 10.1016/0959-8049(92)90447-A

DO - 10.1016/0959-8049(92)90447-A

M3 - Article

C2 - 1627368

VL - 28A

SP - 1023

EP - 1028

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 1879-0852

IS - 6-7

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454